A randomized, single-blind evaluation of the Elixir DESyne BD novolimus-eluting coronary stent system with resorbable polylactide-based polymer compared with the Medtronic Endeavor zotarolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions

Trial Profile

A randomized, single-blind evaluation of the Elixir DESyne BD novolimus-eluting coronary stent system with resorbable polylactide-based polymer compared with the Medtronic Endeavor zotarolimus-eluting coronary stent system in the treatment of patients with de novo coronary artery lesions

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 02 Nov 2016

At a glance

  • Drugs Novolimus (Primary) ; Zotarolimus
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Registrational; Therapeutic Use
  • Acronyms EXCELLA-BD
  • Sponsors Elixir Medical Corporation
  • Most Recent Events

    • 03 Sep 2013 Results presented at the ESC Congress 2013: Annual Congress of the European Society of Cardiology.
    • 24 May 2013 2-year results reported in an Elixar Medical Corporation media release and presented at EuroPCR.
    • 11 Mar 2013 Interim (6 and 24 month) results presented at the 62nd Annual Scientific Session of the American College of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top